TrialClinical cancer research : an official journal of the American Association for Cancer Research2021

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.

Preeti Narayan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.